Portfolio breakdown

POSITIONS
Amgen
9.4%
Gilead Sciences
8.3%
Vertex Pharmaceuticals
7.8%
Argenx SE
7.4%
Regeneron Pharmaceuticals
5.7%
Revolution Medicines
5.4%
Insmed
4.5%
Viridian Therapeutics
3.9%
Biogen
3.6%
Oruka Therapeutics
3.6%
Scholar Rock
3.6%
Vaxcyte
3.5%
Relay Therapeutics
3.0%
United Therapeutics Corporation
2.6%
BridgeBio Pharma
2.1%
Enliven Therapeutics
1.8%
Immunocore
1.8%
Alnylam Pharmaceuticals
1.6%
Incyte
1.6%
Jade Biosciences
1.6%
Rivus Pharmaceuticals
1.5%
Axsome Therapeutics
1.2%
Kodiak Sciences
1.2%
Damora Therapeutics
1.1%
Avalyn Pharma
1.0%
Disc Medicine
1.0%
CG Oncology
0.9%
Spyre Therapeutics
0.9%
Summit Therapeutics
0.9%
Alto Neuroscience
0.8%
Krystal Biotech
0.7%
LB Pharmaceuticals
0.7%
Tango Therapeutics
0.7%
Eupraxia Pharmaceuticals
0.6%
Palvella Therapeutics
0.6%
Seaport Therapeutics
0.6%
Yarrow Bioscience
0.6%
Hemab Therapeutics
0.5%
Bicara Therapeutics
0.4%
Parabilis Medicines
0.4%
Soufflé Therapeutics
0.4%
Aura Biosciences
0.2%
Niroda Therapeutics
0.1%
Therapeutic Area
Diversified
Inflammation & Immunology
Solid Tumors
Infectious Diseases
Neurology & Psychiatry
Cardiometabolic Diseases
Hematology
Others
Technology
Small Molecule
Biologics
RNA
Gene- and cell therapy
Market Capitalization (in USD)
> 30 bn
5 - 30 bn
1 - 5 bn
500 mn - 1 bn
<500 mn
Private

Facts & key figures

Investment Focus

Innovative biotechnology companies developing differentiated therapies

Primarily invested in listed biotechnology companies, with selective private investments

20-50 target participations

5–8 core positions with meaningful portfolio weights

suitability & risk profile
Designed for long-term investors (5+ years) willing to accept equity risk typical of the biotech sector.
Lower Risk
Higher Risk
Risk metrics (3Y)
NBI (Nasday Biotechnology Index) is used as the benchmark and the reference currency is CHF.
general information

Benefits & risks

Access to global biotech growth

Diversified portfolio of profitable and pipeline companies

Experienced investment management

Dividend policy (3-5%)

Equity volatility

Biotech sector swings

Currency risks

Discount/premium to NAV

Up to 15% leverage possible